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Does home based medication review keep older people out of
hospital? The HOMER randomised controlled trial
Richard Holland, Elizabeth Lenaghan, Ian Harvey, Richard Smith, Lee Shepstone, Alistair Lipp, Maria Christou,
David Evans, Christopher Hand
Abstract
Objective To determine whether home based medication
review by pharmacists affects hospital readmission rates among
older people.
Design Randomised controlled trial.
Setting Home based medication review after discharge from
acute or community hospitals in Norfolk and Suffolk.
Participants 872 patients aged over 80 recruited during an
emergency admission (any cause) if returning to own home or
warden controlled accommodation and taking two or more
drugs daily on discharge.
Intervention Two home visits by a pharmacist within two weeks
and eight weeks of discharge to educate patients and carers
about their drugs, remove out of date drugs, inform general
practitioners of drug reactions or interactions, and inform the
local pharmacist if a compliance aid is needed. Control arm
received usual care.
Main outcome measure Total emergency readmissions to
hospital at six months. Secondary outcomes included death and
quality of life measured with the EQ-5D.
Results By six months 178 readmissions had occurred in the
control group and 234 in the intervention group (rate
ratio = 1.30, 95% confidence interval 1.07 to 1.58; P = 0.009,
Poisson model). 49 deaths occurred in the intervention group
compared with 63 in the control group (hazard ratio = 0.75,
0.52 to 1.10; P = 0.14). EQ-5D scores decreased (worsened) by a
mean of 0.14 in the control group and 0.13 in the intervention
group (difference = 0.01, − 0.05 to 0.06; P = 0.84, t test).
Conclusions The intervention was associated with a
significantly higher rate of hospital admissions and did not
significantly improve quality of life or reduce deaths. Further
research is needed to explain this counterintuitive finding and
to identify more effective methods of medication review.
Introduction
Twenty eight per cent of all prescribed drugs in the United King-
dom are consumed by the 7% of the population aged over 751 2;
6.5% of hospital admissions have recently been shown to be
related to adverse drug reactions, and these are significantly
more likely to occur in older patients.3 This may be due to a
combination of factors, including polypharmacy and age related
physiological changes. Older patients can also have considerable
problems with adhering to their drug regimens—up to 50% of
prescribed drugs are estimated to be not taken as prescribed.4 5
The national service framework for older people and the
NHS plan recommend regular medication reviews for older
patients to maximise therapeutic benefit and minimise potential
harm.6 7 Historically, UK studies of medication review have
focused on prescribing outcomes rather than effects on hospital
admissions.8–10 An Australian study of a home based medication
review-type intervention showed a 25% reduction in admissions
and a reduction in deaths outside hospital.11 We sought to inves-
tigate the effectiveness of home based medication review in
terms of its impact on hospital admissions in the United
Kingdom. We chose home visits to ensure that the intervention
could reach all very elderly participants. We also considered that
home visits would allow pharmacists to gain greater insight into
patients’ methods of managing their drugs. The trial involved a
large number of pharmacists delivering the intervention to
ensure its generalisability.
Methods
Recruitment and assignment
Researchers recruited patients from four general hospitals and
six community hospitals if they were aged 80 or over, admitted as
an emergency, intended to be discharged to their own home or
warden controlled accommodation, and prescribed two or more
drugs on discharge. Exclusion criteria were dialysis treatment
and participation in an intensive discharge service on one site.
We randomised patients to receive home based medication
review or usual care. We used third party telephone randomisa-
tion based on a computer generated sequence in blocks of vary-
ing length. Randomisation was stratified by abbreviated mental
test score (score ≥ 8 v < 8)12 and whether the patient was living
alone. We obtained written informed consent from all
participants.
Pharmacists could participate if they held a postgraduate
qualification in pharmacy practice or had recent continuing pro-
fessional development in therapeutics. All pharmacists partici-
pated in a two day training course, including lectures on adverse
drug reactions, prescribing in elderly people, improving
concordance, and communication skills.
The intervention
Initial referral to a review pharmacist included a copy of the
patient’s discharge letter. Pharmacists arranged home visits at
times when they could meet patients and carers. Pharmacists
assessed patients’ ability to self medicate and drug adherence,
and they completed a standardised visit form. Where
appropriate, they educated the patient and carer, removed out of
date drugs, reported possible drug reactions or interactions to
the general practitioner, and reported the need for a compliance
aid to the local pharmacist. Where a compliance aid was recom-
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mended, this was provided within the trial and a filling fee was
paid to the local pharmacist. One follow up visit occurred at six
to eight weeks after recruitment to reinforce the original advice.
Masking and the control group
Because of the nature of the intervention, no “placebo” could be
provided. Participants were told after randomisation which
group they were in. Those in the control group received “usual
care.” It is possible that a small number of patients in both groups
may have had their medication reviewed during the follow up
period by their general practitioner or community pharmacist.
Outcome data and analysis
The primary outcome was total number of emergency
admissions to hospital over six months. Secondary outcomes
included deaths, admissions to residential homes and nursing
homes, and self assessed quality of life measured using the
EQ-5D.13–15 Utility scores, as measured by the EQ-5D, can vary
from 1 (perfect health) to − 0.59 (worst imaginable health state).
Patients also rated their health on a visual analogue scale from
100 (perfect health) to 0 (worst imaginable health).
We collected data on emergency admissions from hospital
episode statistics. The Office for National Statistics provided
mortality data. In addition, the project coordinator contacted all
patients by telephone at three months and six months to collect
data on admissions to nursing homes and residential homes and
to maximise the response to mailed quality of life questionnaires.
In addition, we collected data from practices containing more
than 10 trial patients on home visits by general practitioners,
attendance at general practices, and items prescribed over the six
month follow up.
We used Poisson regression to compare the number of
admissions between groups. We used survival analysis to
compare mortality between the two groups by using the Cox
proportional hazard ratio. In both analyses, we adjusted for the
two stratification variables (living alone and confusion). We ana-
lysed the proportions admitted to nursing homes or residential
homes by using the 2 test.We assumed that changes in quality of
life followed a normal distribution and analysed them by using
the two sample t test. We compared home visits by general prac-
titioners and attendance at general practices by using Poisson
regression, entering practices into the model as a random effect.
We analysed data according to randomisation group,
irrespective of whether or not the patients received the interven-
tion as planned (the intention to treat principle). We used Stata
version 8.0 with statistical significance at the 5% level.
Sample size calculation
Local admission data showed a mean of 0.8 readmissions per
patient within six months of discharge. A previous randomised
controlled trial suggested that readmissions could be reduced by
25% in six months.11 We aimed to show a more conservative
reduction of 20%. Sample size calculations based on a normal
approximation to the Poisson distribution indicated that we
needed to recruit 850 patients to have 90% power to show this
reduction at the 5% significance level.
Results
Participant flow and follow up
We invited 1399 patients to participate after screening them for
eligibility between October 2000 and December 2002; 872 (62%)
patients agreed and were randomised (fig 1). We excluded 17
recruited patients after randomisation. Reasons for exclusion
were elective baseline admission (n = 5), discharge to nursing or
residential home (5), death before discharge (4), previously
recruited (2), and taking fewer than two drugs (1). Table 1 shows
that the two groups were very similar at baseline. Twenty patients
withdrew from the trial, and six moved from the study area. Pri-
mary outcome data were thus available for 829 (97%) patients.
Review pharmacists and intervention visits
We recruited 22 review pharmacists. Of 429 patients in the inter-
vention group, 362 received first visits. Reasons for not visiting
were visit not wanted (46 patients), pharmacist unavailable (11
patients), and patient unavailable due to death or early readmis-
sion (10 patients). Review pharmacists carried out a mean of 17
(range 1-37) first visits. More than 90% of first visits occurred
within two weeks of recruitment (mean 7.2 days), and visits lasted
a mean (SD) of 61 (23) minutes. Second visits were conducted for
297 patients and took a mean (SD) of 42 (19) minutes. Visits
generated a total of 933 recommendations or comments to gen-
eral practitioners (2.58/visited patient); 120 of these referred to
possible drug reactions or interactions in 81 patients (22% of vis-
ited patients).
Compliance aids and pharmacists’ view of intervention
Review pharmacists recommended compliance aids in 39
patients (11% of those receiving first visits). Pharmacists were
asked after their second visit to record whether they believed the
visits had been useful. For 216 (73%) patients, pharmacists felt
the visits were definitely or probably useful; for 81 (27%) patients,
pharmacists felt the visits were unlikely to be useful or not at all
useful, generally when patients were found to be coping very
well.
Number of hospital readmissions
A total of 178 emergency readmissions occurred in the control
group and 234 in the intervention group (table 2). The Poisson
model indicated a 30% greater rate of readmission in the
intervention group (rate ratio = 1.30, 95% confidence interval
1.07 to 1.58; P = 0.009).
Registered/eligible patients (n=1399)
Randomisation (n=872) (62% eligible patients)
Control (n=435)
Post-randomisation exclusions (n=9)
Intervention (n=437)
Post-randomisation exclusions (n=8)
Lost to follow up
Moved out of study area (n=2)
Received intervention as
 allocated (n=362)
Did not receive intervention as
 allocated (n=67)
Refused/unable to participate (n=527)
 Did not wish to participate (n=339)
 Did not want help/visit (n=109)
 Confused or unable to answer questions (n=51)
 Other reason or not recorded (n=28)
Lost to follow up
Moved out of study area (n=4)
Analysed (n=415)
Excluded from analysis: 
Withdrawn from primary
outcome (n=12)
Analysed (n=414)
Excluded from analysis: 
Withdrawn from primary
outcome (n=8)
Fig 1 Flowchart showing progress of patients through the HOMER trial
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Secondary outcomes
Mortality data were available for 829 (97%) patients. Fewer
deaths occurred in the intervention group (49 v 63). Figure 2
shows the Kaplan-Meier survival graph. The hazard ratio for the
intervention group compared with the control group was 0.75
(0.52 to 1.10; P = 0.14). Data on residential or nursing home
admissions were available on fewer patients, as these were
collected by telephone (585, 68%). Table 3 shows that fewer con-
trol patients than intervention patients were admitted to residen-
tial or nursing homes, but again these differences were not
statistically significant.
Quality of life data
Change in utility scores could be calculated for 308/380 (81%)
surviving intervention patients and 284/362 (78%) surviving
control patients. Both groups’ scores decreased over the six
month follow up period, but the changes were not significantly
different between the groups (table 4). Scores on the visual ana-
logue health scale also fell; the difference of 4.1 (95% confidence
interval 0.15 to 8.09) units in favour of the control group was sta-
tistically significant (P = 0.042).
Primary care data
We included 165 patients from 12 practices in this analysis (84
intervention, 81 control). General practitioners carried out 204
home visits in the intervention group and 125 in the control
group, a difference of 43% (rate ratio = 1.43, 1.14 to 1.80;
P = 0.002). No statistically significant differences occurred
between the groups in attendance at general practices or
prescription items received.
Discussion
This trial shows that home based medication review by a
pharmacist does not reduce emergency hospital admissions.
Indeed, the intervention seemed to increase admissions by 30%
and home visits by general practitioners by 43%. This finding was
not balanced by improvements in quality of life. Although the
overall EQ-5D utility score decreased in both groups, with no
between group difference, scores on the visual analogue health
scale decreased less in the control group than in the intervention
group.
In terms of numbers of deaths, results were not statistically
significant but favoured the intervention group, with a hazard
ratio of 0.75. Although this result seems clinically important, it
should be noted that the confidence interval was wide (0.52 to
1.10).
Validity of trial
This trial was large, involving more than 850 patients. The entry
criteria ensured a broad sample of elderly people discharged
from hospital, which, together with the relatively high participa-
tion rate and the large number of pharmacists involved, means
that the generalisability of these results should be high. Follow up
of the main outcome was good—only 3% of participants
withdrew or were lost to follow up. Hospital admission data were
provided by downloads from hospital episode statistics, which
are unlikely to have introduced bias. Quality of life data were
provided by almost 80% of patients. Slightly more intervention
patients than controls provided these at six months (81% v 78%),
which could have introduced a bias. At three months, however,
when response was almost equal, no between group differences
were apparent on either quality of life measure. Overall, the
internal validity of this study seems high, although it should be
Table 1 Baseline comparison of intervention and control group patients.
Values are numbers (percentages) unless stated otherwise
Characteristic Intervention group (n=429) Control group (n=426)
Female 262 (61.1) 272 (63.8)
Mean (SD) age (years) 85.4 (4.0) 85.5 (4.0)
Living alone 263 (61.3) 268 (62.9)
Mean (SD) abbreviated
mental test
8.9 (1.6) 8.9 (1.5)
Mean (SD) daily drugs 6.0 (2.7) 5.8 (2.3)
Mean (SD) total drugs 6.4 (2.8) 6.3 (2.5)
Monitored dose system* 81 (19.8) 71 (17.4)
Social class (I, II, IIInm)† 170 (42.6) 163 (41.4)
Mean (SD) length of baseline
admission (days)
13.6 (14.6) 13.4 (15.3)
Mean (SD) days from
recruitment to discharge
1.7 (3.9) 1.8 (7.0)
Baseline diagnosis
Cardiovascular (total): 134 (31.2) 144 (33.8)
Myocardial
infarction/angina
57 (13.3) 65 (15.3)
Heart failure 38 (8.9) 34 (8.0)
Musculoskeletal (total): 61 (14.2) 65 (15.3)
Fracture 37 (8.6) 40 (9.4)
Gastrointestinal (total) 47 (11.0) 54 (12.7)
Respiratory (total): 48 (11.2) 49 (11.5)
COPD/asthma 15 (3.5) 13 (3.1)
Lower respiratory tract
infection
16 (3.7) 22 (5.2)
Neurological: 40 (9.3) 25 (5.9)
Stroke/transient ischaemic
attack
16 (3.7) 14 (3.3)
Senility/dementia 16 (3.7) 6 (1.4)
Genitourinary 17 (4.0) 16 (3.8)
Cancer (total) 15 (3.5) 7 (1.6)
Other or unclassified 67 (15.6) 66 (15.5)
COPD=chronic obstructive pulmonary disease.
*Monitored dose system data available for only 817 patients (409 intervention and 408
control).
†Employment details available for only 793 patients (399 intervention and 394 control).
Table 2 Number of emergency hospital readmissions by group during six month trial follow up
Group
No of readmissions
Total admissions Person years of follow up0 1 2 3 4 5 6
Intervention 253 113 34 10 3 1 1 234 195.0
Control 281 99 26 5 3 0 0 178 191.6
Analysis time (days)
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Fig 2 Survival analysis over six month follow up period for patients in the
HOMER trial
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noted that follow up was only for six months. Longer term ben-
efits might have emerged had follow up been longer. However,
we can envisage no theoretical grounds for a delayed benefit
emerging long after the intervention had ceased.
These results seem counterintuitive. The reviews were
intended to help patients to understand their drugs better,
reduce adverse drug reactions,3 and help patients to adhere to
their drug regimens.We did not measure any of these intermedi-
ate outcomes directly. However, we hypothesised that the
intervention would lead to a reduction in readmissions through
these effects and seemed unlikely to cause harm. The
pharmacists providing the interventions considered that in more
than 70% of cases their interventions had probably or definitely
been of value. Thus, we are left to explain how these
interventions increased hospital admissions.
Possible explanations
Given the high internal validity of this study, its results are
unlikely to be explained by bias or confounding. We cannot
exclude the possibility of a type I error (chance). If, however, we
consider the findings to be causally related, three possible expla-
nations should be considered. The first is that pharmacists did
help patients to understand their conditions better. This could
have led patients to recognise warning signs earlier and
promoted better help seeking behaviour, leading to more hospi-
tal admissions. This positive view is weakly supported by the
non-significant decrease in deaths observed. Indeed, by prevent-
ing deaths of frailer patients our interventionmay have increased
admissions and general practitioner home visits—so-called
“competing outcomes.”
Two less favourable interpretations are possible, however.
Previous studies have shown that interventions of this type by
pharmacists tend to increase adherence to prescribed drugs.16–19
Our patients were prescribed large numbers of daily drugs
(mean = 5.9/day). By encouraging better adherence, our
pharmacists may have precipitated iatrogenic illness that
previously had been avoided. Given the very elderly group stud-
ied, we did not collect data on adherence as we did not wish to
burden patients with extra questionnaires beyond our quality of
life assessment. This means that we cannot be sure that
adherence improved. Indeed, another study using pharmacists to
improve discharge from hospital found no effect on adherence.20
Finally, by visiting our patients at home and spending
reasonably long periods of time there, we may simply have added
to the complexity of their care. This may have increased anxiety
and confusion or dependence on health services. The
intervention group’s scores on the visual analogue health scale
fell more markedly than those of the control group. This suggests
that they viewed their overall health as having worsened and may
support a view that our intervention made patients focus more
on their problems.
Evidence from other trials
Since this trial started, three large UK studies of community
based medication review in elderly people have been
published.20–22 Two showed non-significant decreases in admis-
sions,20 21 whereas the other showed a non-significant increase in
admissions.22 These results, in combination with ours, indicate
that it cannot be assumed that community based medication
review necessarily reduces admissions, despite evidence from
overseas.11 Although our finding on mortality is potentially
encouraging, UK results on this outcome are equivocal, with
mixed, non-significant results.20–22
Evidence in the field of medication review is growing rapidly.
More positive results seem to have resulted from interventions
focused on diseases such as heart failure.10 Alternative models to
home visiting also exist, including reviews within a general prac-
tice surgery.22 Such a review has the advantage of access to full
patient records, potentially allowing a more thorough clinical
medication review than was possible within this study. In
addition, it allows pharmacists to build up a close working
relationship with general practitioners, which is vital if the phar-
macists’ recommendations are to be followed.
Conclusions
Our trial suggests that home based medication review for older
people recently discharged from hospital increased, rather than
decreased, hospital admissions. It also seemed to worsen
patients’ quality of life compared with controls. The exact
mechanism for this result is not apparent. Patients may have
adhered better to their drugs, with a resultant increase in side
effects or drug interactions. Alternatively, our intervention may
have provoked better understanding and help seeking
Table 3 Number of admissions to residential or nursing homes by group
during six month trial follow up
Admissions
No (%) of events Difference‡ in
proportions, with 95%
CI and P value§
Intervention
group (n=429)*
Control group
(n=426)†
Total No admitted to
residential home
21 (7.0) 17 (6.0) 1.0
(−3.1 to 5.2; P=0.61)
Total No admitted to
nursing home
16 (5.3) 15 (5.3) 0.001
(−3.8 to 3.8; P=0.97)
*Data available for 300 intervention patients.
†Data available for 285 control patients.
‡Intervention minus control.
§2 test.
Table 4 Mean EQ-5D scores and visual analogue health scale scores for groups at baseline, three months, and six months follow up
Measure
Intervention group (n=429) Control group (n=426) Difference* in change over six
months, with 95% CI and P
value†Score (SD) No of respondents Score (SD) No of respondents
EQ-5D
Baseline 0.59 (0.29) 422 0.63 (0.28) 417
Three months 0.47 (0.32) 320 0.48 (0.32) 325
Six months 0.46 (0.33) 311 0.50 (0.31) 288
Change over six months −0.131 (0.33) 308 −0.137 (0.34) 284 0.006 (−0.048 to 0.059; P=0.84)
Visual analogue health scale
Baseline 62.2 (18.3) 404 62.3 (18.5) 406
Three months 54.3 (19.5) 322 55.6 (20.1) 315
Six months 54.9 (19.8) 303 58.8 (19.4) 275
Change over six months −7.36 (24.4) 284 −3.24 (23.0) 266 −4.12 (−8.09 to −0.15; P=0.042)
*Intervention minus control.
†t test.
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behaviour. Either way, a growing body of evidence suggests that
further research is necessary to elucidate the most effective form
and detailed effects of medication review. The recommendation
in the national service framework for older people that this
should be widely introduced in primary care seems to lack a clear
evidence base.7
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What is already known on this topic
Adverse drug reactions are an important cause of
admission to hospital in elderly people
Patients have problems adhering to complex drug regimens
Medication review is recommended as a technique to
reduce these problems
What this study adds
Home based medication review by pharmacists may
increase hospital admissions
More effective forms of medication review need to be
established, considering patients’ quality of life and effects
on both hospital and general practice, as well as prescribing
outcomes
Amendment
This is Version 2 of the paper. In this version, the statistical
power is given as 90% [rather than 80% as in the previous
version] and the trial ISRCTN is included [omitted from the
previous version].
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